Headquartered in Charleston, South Carolina, FibroBiologics, LLC, is a pioneering early-stage pharmaceutical company focused on developing innovative biologics for the treatment of fibrotic diseases. Founded in June 2016 by Drs. Galina Bogatkevich and Richard Silver, FibroBiologics is developing the novel peptide “M10” with significant anti-fibrotic and anti-inflammatory potential. The company’s mission is to transform the treatment landscape for scleroderma (systemic sclerosis), idiopathic pulmonary fibrosis, and other fibrotic diseases, which account for significant morbidity and mortality and impose a substantial economic burden.

Innovation is at the heart of everything FibroBiologics, LLC does. As a spinout from the Medical University of South Carolina (MUSC), the company benefits from access to MUSC’s robust innovation ecosystem and resources. The collaboration with MUSC’s Zucker Institute for Innovation Collaboration ensures FibroBiologics remains at the cutting edge of technology transfer and entrepreneurial growth.

FibroBiologics, LLC, is committed to translating scientific discoveries into therapeutic realities that improve patient outcomes and reduce healthcare costs associated with fibrosis-related conditions globally.